BCM
CYTK icon

Bridgeway Capital Management’s Cytokinetics CYTK Stock Holding History

Bridgeway Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-53,633
Closed -$256K – 1482
2014
Q2 		$256K Hold
53,633
– – 0.01% 1292
2014
Q1 		$510K Hold
53,633
– – 0.01% 1069
2013
Q4 		$349K Hold
53,633
– – 0.01% 1184
2013
Q3 		$406K Buy
+53,633
New +$575K 0.01% 1129

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's CYTK Position: Q3 2014 in Review

Bridgeway Capital Management sold out of Cytokinetics (CYTK) in Q3 2014, closing a stake of 53,633 shares — an estimated $256K sold.

Bridgeway Capital Management first reported a position in CYTK in Q3 2013 and held it in 4 quarters. The position peaked at $510K in Q1 2014. 85 funds tracked by Wall St. Rank hold CYTK as of Q3 2014.

  • Bridgeway Capital Management reported no remaining Cytokinetics position as of Q3 2014 after selling out during the quarter.
  • Bridgeway Capital Management sold 53,633 Cytokinetics shares in Q3 2014, an estimated $256K.
  • Bridgeway Capital Management first reported a position in Cytokinetics in Q3 2013 and held it in 4 quarters.
  • Bridgeway Capital Management's Cytokinetics position peaked at $510K in Q1 2014.
  • 85 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2014.

Based on Bridgeway Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.